Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).

Fan Xia Yaqi WangHui WangLijun ShenZuolin XiangYutian ZhaoHuojun ZhangJuefeng WanHui ZhangYan WangRuiyan Wu Jingwen WangWang YangMenglong ZhouShujuan ZhouYajie ChenZhiyuan ZhangXian WuYan XuanRenjie WangYiqun SunTong TongXun ZhangLei WangDan HuangWeiqi ShengHao YanXu YangYuxin ShenYu XuRuping ZhaoMiao MoGuoxiang CaiSanjun CaiYe Xu Zhen Zhang

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

The iTNT regimens remarkably improved CR rates in pMMR/MSS LARC compared with historical benchmark with acceptable toxicity. Up-front SCRT followed by immunochemotherapy was selected for future definitive study.

Keyphrases

locally advanced
rectal cancer
neoadjuvant chemotherapy
phase ii study
squamous cell carcinoma
radiation therapy
open label
placebo controlled
double blind
diffuse large b cell lymphoma
phase iii
current status
oxidative stress
randomized controlled trial
clinical trial
phase ii